Go Deep
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,148 | 12.7 | 1.82 | 0.77 | 2,103.87 |
| Oct 2026 | 21,138 | 12.7 | 1.82 | 0.77 | 2,103.82 |
| Oct 2026 | 21,180 | 12.6 | 1.81 | 0.77 | 2,087.39 |
| Oct 2026 | 21,112 | 12.8 | 1.83 | 0.77 | 2,115.27 |
| Oct 2026 | 21,039 | 12.9 | 1.86 | 0.77 | 2,142.27 |
| Oct 2026 | 21,101 | 12.8 | 1.83 | 0.77 | 2,119.50 |
Hikma Pharmaceuticals PLC Quarterly Results
Quarterly data isn't available for this company right now.
Hikma Pharmaceuticals PLC Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 3,349,000,000.0 | 3,127,000,000.0 | 2,875,000,000.0 | 2,517,000,000.0 | — |
| Net Profit | 402,000,000.0 | 359,000,000.0 | 190,000,000.0 | 188,000,000.0 | — |
| EPS | 1.8 | — | 0.9 | 0.8 | 1.8 |
Hikma Pharmaceuticals PLC Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 5,671,000,000.0 | 5,133,000,000.0 | 4,680,000,000.0 | 4,471,000,000.0 | — |
| Total Liabilities | 3,065,000,000.0 | 2,812,000,000.0 | 2,471,000,000.0 | 2,323,000,000.0 | — |
| Total Equity | 2,593,000,000.0 | 2,310,000,000.0 | 2,198,000,000.0 | 2,135,000,000.0 | — |
Owes vs Owns
Hikma Pharmaceuticals PLC owed $0.56 for every $1 it owned in Jun 2026, up from $0.52 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.56× | 0.54× | 0.55× | 0.53× | 0.52× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Hikma Pharmaceuticals PLC Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 4.3%Receivables 17.6%Inventory 19.5%Fixed assets (tangible) 25.5%Intangible assets 20.6%Other assets 12.3%
How it's funded — Dec 2025
Short-term debt 1.9%Long-term debt 25.5%Payables 7.1%Other liabilities 19.6%Shareholders' equity 46.0%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 243.0 | 213.0 | 229.0 | 292.0 |
| Receivables | 997.0 | 896.0 | 789.0 | 777.0 |
| Inventory | 1,106.0 | 986.0 | 891.0 | 776.0 |
| Fixed assets (tangible) | 1,448.0 | 1,326.0 | 1,141.0 | 1,081.0 |
| Intangible assets | 1,170.0 | 1,156.0 | 1,100.0 | 1,124.0 |
| Long-term investments | 11.0 | 11.0 | 10.0 | 10.0 |
| Other assets | 696.0 | 545.0 | 520.0 | 411.0 |
| Liabilities & equity | ||||
| Short-term debt | 106.0 | 642.0 | 150.0 | 139.0 |
| Long-term debt | 1,445.0 | 607.0 | 975.0 | 1,074.0 |
| Payables | 400.0 | 358.0 | 309.0 | 291.0 |
| Other liabilities | 1,114.0 | 1,205.0 | 1,037.0 | 819.0 |
| Shareholders' equity | 2,606.0 | 2,321.0 | 2,209.0 | 2,148.0 |
| Net tangible assets | 1,423.0 | 1,154.0 | 1,098.0 | 1,011.0 |
Hikma Pharmaceuticals PLC Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 436,000,000.0 | 564,000,000.0 | 608,000,000.0 | 585,000,000.0 | — |
| Investing Activities | -388,000,000.0 | -381,000,000.0 | -333,000,000.0 | -607,000,000.0 | — |
| Financing Activities | -25,000,000.0 | -188,000,000.0 | -337,000,000.0 | -58,000,000.0 | — |